Ocugen’s OCU400 Phase 3 plus Korean licensing underpin potential 2026 BLA remains the company’s best bet at its first commercial gene therapy revenue. OCU410ST also received a Rare Pediatric Disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback